z-logo
open-access-imgOpen Access
Activity of Bisnaphthalimidopropyl Derivatives against Trypanosoma brucei
Author(s) -
Nuno A. G. Graça,
Luís Gaspar,
David Costa,
Inês Loureiro,
Paul Kong Thoo Lin,
Isbaal Ramos,
Meritxell Roura,
Alain Pruvost,
Ian K. Pemberton,
Hadjer Loukil,
Jane MacDougall,
Joana Tavares,
Anabela CordeirodaSilva
Publication year - 2016
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02490-15
Subject(s) - trypanosoma brucei , biology , pharmacology , microbiology and biotechnology , biochemistry , gene
Current treatments for African trypanosomiasis are either toxic, costly, difficult to administer, or prone to elicit resistance. This study evaluated the activity of bisnaphthalimidopropyl (BNIP) derivatives againstTrypanosoma brucei BNIPDiaminobutane (BNIPDabut), the most active of these compounds, showedin vitroinhibition in the single-unit nanomolar range, similar to the activity in the reference drug pentamidine, and presented low toxicity and adequate metabolic stability. Additionally, using a murine model of acute infection and live imaging, a significant decrease in parasite load in BNIPDabut-treated mice was observed. However, cure was not achieved. BNIPDabut constitutes a new scaffold for antitrypanosomal drugs that deserves further consideration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom